Fundraising FoxNextech Invest — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.
BiotechHealthtechMedical DevicesRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)
Board seatThilo Schroeder· per SEC Form D
Co-investorsBain Capital Life SciencesForesite CapitalGen CapitalGV (Google Ventures)Illinois VenturesThe Column Group+2 more
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)in
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsElm Street VenturesRA Capital+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.